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A combination of Telomerase inhibitor, MST-312 and doxorubicin synergistically
induce apoptosis in B-lymphoblastic leukemia cell line NALM-6
Abstract
There have been consistent efforts in concomitant administration of chemotherapy drugs such
as doxorubicin with another more tumor-specific drug in order that increase sensitivity of
tumor cells to the cytotoxicity of doxorubicin and reduce necessary therapeutic dosage.
Using telomerase-targeted therapy for cancer has mentioned due to unlimited replicative
potential obtained from high expression of telomerase enzyrnes by cancer cells. It's whiles
telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells.
Materials and Methods:
This study was aimed to investigate
doxorubicin to enhance doxorubicin
viability, cell cytotoxicity, apoptosis,
related target genes were performed
alone and in combination.
the effect of combination treatment of MST-312 and
therapy efficacy in NALM-6 cells. Evaluation of cell
and qRT-PCR of c-Myc, hTERT, and other apoptosis-
after 48h in cells treated with MST-312, doxorubicin
Results:
Our results showed that cell viability of NALM-6 cells was inhibited after treatment with
MST-312 or doxorubicin alone by a dose-dependent manner, and the drug combination also
synergistically inhibited cell viability. Also this synergism effect was observed in induced
augmentation of cytotoxicity and apoptosis. Consistantly, The mRNA expression of Bcl-2
was reduced and the mRNA level of Bax and Bax/Blc-2 ratio was up-regulated significantly
following co-treatment with doxorubicin and MST-312 in NALM-6 cells, which confirm
synergistic effect of MST-312 and doxorubicin against apoptosis. Also our results
demonstrated that the drug combination significantly suppressed both c-Myc and hTERT
mRNA level inNALM-6 cells.
I)isscusion:
It seems that combination of MST-312 and doxorubicin maybe a beneficial therapy for ALL
treatonent; as respects, supplementary investigation in molecular mechanism and clinical hial
is necessery for trusty application of this combination therapy in ALL therapy.
Keywords: Telomerase, MST-3 12, doxorubicin, NALM-6
OI-rt s5J,1l. pgLe ol5:l':
ot5lijt; oJ*os3 +Yae:
a.U Ol*lr" 1l gLic @ sy
.s1;1r:.+Ui Of d*: *i1l o*,L,i.1l5 ,g9.?dilo -l{ro .,4.-1tg o..fi dte ,s!ia'd a'U Ok\ a*stlo a"'J2
-lo MST-312 jt-ro:X o.r:5.11+* rit ,r*rtf Oll:s: ,r.at Olst' .#f pgJs ol5i-,ijlo ,r5;!.,4l.g, o.t5iti,jlc Ogi
Nalm-6 cb d{:r*r*9rJJ ocl ,rJ9J*o J-p *,jj , cc 'ls L, ,-J;.. vJJ
:jl Js,i.b gll9lo oL^o ptL*.o.5Liicl )9@ \ lY/'f/ 'Y tsy a;-'i$- jSi 'lY c'sL'r.,o
,".fctg;l> nU r eU




(,r.blc) 6l;9lo *lP ye 4,.,*LS Cr* 613..ar,o)Li ;5o
(.*tU) gt19lc otP 9*&: cocll.r.i:q all.qc;5s
,st-^SJ c,)L-,a.*, o.r.l.r. Lo.!: o/rLj .S.tP;Jo
